Pramlintide reduced markers of oxidative stress in the postprandial period in patients with type 2 diabetes.

Ceriello A, Lush CW, Darsow T, Piconi L, Corgnali M, Nanayakkara N, Frias JP, Maggs D

Diabetes/metabolism research and reviews1 Feb 2008Cited by 13 (Europe PMC)

PMID17694505DOI10.1002/dmrr.765PepBankPUB-17694505

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

4 results from studies that gave the peptide. 4 results from people.

01HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, pramlintide reduced postprandial glucose excursions versus placebo.
In plain wordsIn patients with type 2 diabetes, pramlintide reduced glucose rises after meals compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreasePostprandial glucose excursions
Study
n = 19
Comparator
Placebo
Outcome group
Glycemic control · Metabolic and weight
Studied dose
120 microgAs given in this study (human).
Source sentences
Summary
Compared to placebo, pramlintide treatment reduced postprandial excursions of glucose, NT, and OxLDL-C and protected TRAP from consumption.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, single-blind, placebo-controlled, crossover study conducted at two clinical research centres in the United States.
Summary · context
A total of 19 subjects (9 men and 10 women) with type 2 diabetes using mealtime insulin participated in the study.
Summary · context
Pramlintide (120 microg), or placebo, and rapid-acting mealtime insulin were administered prior to a standardized meal on two separate study days.
Report a problemFND-1769450501
02HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, pramlintide reduced postprandial nitrotyrosine excursions versus placebo.
In plain wordsIn patients with type 2 diabetes, pramlintide reduced nitrotyrosine rises after meals compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseNitrotyrosine excursions
Study
n = 19
Comparator
Placebo
Outcome group
Oxidative stress · Metabolic and weight
Studied dose
120 microgAs given in this study (human).
Source sentences
Summary
Compared to placebo, pramlintide treatment reduced postprandial excursions of glucose, NT, and OxLDL-C and protected TRAP from consumption.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, single-blind, placebo-controlled, crossover study conducted at two clinical research centres in the United States.
Summary · context
A total of 19 subjects (9 men and 10 women) with type 2 diabetes using mealtime insulin participated in the study.
Summary · context
Pramlintide (120 microg), or placebo, and rapid-acting mealtime insulin were administered prior to a standardized meal on two separate study days.
Report a problemFND-1769450502
03HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, pramlintide reduced postprandial oxidized LDL cholesterol excursions versus placebo.
In plain wordsIn patients with type 2 diabetes, pramlintide reduced oxidized LDL cholesterol rises after meals compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseOxidized LDL cholesterol excursions
Study
n = 19
Comparator
Placebo
Outcome group
Oxidative stress · Metabolic and weight
Studied dose
120 microgAs given in this study (human).
Source sentences
Summary
Compared to placebo, pramlintide treatment reduced postprandial excursions of glucose, NT, and OxLDL-C and protected TRAP from consumption.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, single-blind, placebo-controlled, crossover study conducted at two clinical research centres in the United States.
Summary · context
A total of 19 subjects (9 men and 10 women) with type 2 diabetes using mealtime insulin participated in the study.
Summary · context
Pramlintide (120 microg), or placebo, and rapid-acting mealtime insulin were administered prior to a standardized meal on two separate study days.
Report a problemFND-1769450503
04HumanRandomized controlled trialEfficacy outcome
In patients with type 2 diabetes, pramlintide protected total radical trapping parameter from consumption versus placebo.
In plain wordsIn patients with type 2 diabetes, pramlintide preserved antioxidant capacity after meals compared with placebo.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseTotal radical trapping parameter consumption
Study
n = 19
Comparator
Placebo
Outcome group
Oxidative stress · Metabolic and weight
Studied dose
120 microgAs given in this study (human).
Source sentences
Summary
Compared to placebo, pramlintide treatment reduced postprandial excursions of glucose, NT, and OxLDL-C and protected TRAP from consumption.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, single-blind, placebo-controlled, crossover study conducted at two clinical research centres in the United States.
Summary · context
A total of 19 subjects (9 men and 10 women) with type 2 diabetes using mealtime insulin participated in the study.
Summary · context
Pramlintide (120 microg), or placebo, and rapid-acting mealtime insulin were administered prior to a standardized meal on two separate study days.
Report a problemFND-1769450504

Studies that did not test the peptide alone3

In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Pramlintide (Symlin).

05HumanNot a test of Pramlintide (Symlin) aloneObservational studyMechanism
In patients with type 2 diabetes, placebo-corrected glucose incremental AUC was positively associated with nitrotyrosine.
In plain wordsIn patients with type 2 diabetes, placebo-corrected glucose exposure was linked to higher nitrotyrosine.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseGlucose and nitrotyrosine association
Study
n = 19
Outcome group
Oxidative stress · Metabolic and weight
Source sentences
Summary
Correlation analysis revealed positive associations between placebo-corrected glucose incremental AUC(0-4 h) and both NT and OxLDL-C and a negative association between placebo-corrected glucose incremental AUC(0-4h) and TRAP.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, single-blind, placebo-controlled, crossover study conducted at two clinical research centres in the United States.
Summary · context
A total of 19 subjects (9 men and 10 women) with type 2 diabetes using mealtime insulin participated in the study.
Summary · context
Pramlintide (120 microg), or placebo, and rapid-acting mealtime insulin were administered prior to a standardized meal on two separate study days.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1769450505
06HumanNot a test of Pramlintide (Symlin) aloneObservational studyMechanism
In patients with type 2 diabetes, placebo-corrected glucose incremental AUC was positively associated with oxidized LDL cholesterol.
In plain wordsIn patients with type 2 diabetes, placebo-corrected glucose exposure was linked to higher oxidized LDL cholesterol.
Peptide
Pramlintide (Symlin)
Outcome
IncreaseGlucose and oxidized LDL association
Study
n = 19
Outcome group
Oxidative stress · Metabolic and weight
Source sentences
Summary
Correlation analysis revealed positive associations between placebo-corrected glucose incremental AUC(0-4 h) and both NT and OxLDL-C and a negative association between placebo-corrected glucose incremental AUC(0-4h) and TRAP.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, single-blind, placebo-controlled, crossover study conducted at two clinical research centres in the United States.
Summary · context
A total of 19 subjects (9 men and 10 women) with type 2 diabetes using mealtime insulin participated in the study.
Summary · context
Pramlintide (120 microg), or placebo, and rapid-acting mealtime insulin were administered prior to a standardized meal on two separate study days.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1769450506
07HumanNot a test of Pramlintide (Symlin) aloneObservational studyMechanism
In patients with type 2 diabetes, placebo-corrected glucose incremental AUC was negatively associated with total radical trapping parameter.
In plain wordsIn patients with type 2 diabetes, placebo-corrected glucose exposure was linked to lower antioxidant capacity.
Peptide
Pramlintide (Symlin)
Outcome
DecreaseGlucose and TRAP association
Study
n = 19
Outcome group
Oxidative stress · Metabolic and weight
Source sentences
Summary
Correlation analysis revealed positive associations between placebo-corrected glucose incremental AUC(0-4 h) and both NT and OxLDL-C and a negative association between placebo-corrected glucose incremental AUC(0-4h) and TRAP.
3 context sentences(design, population, supporting numbers)
Summary · context
This was a randomized, single-blind, placebo-controlled, crossover study conducted at two clinical research centres in the United States.
Summary · context
A total of 19 subjects (9 men and 10 women) with type 2 diabetes using mealtime insulin participated in the study.
Summary · context
Pramlintide (120 microg), or placebo, and rapid-acting mealtime insulin were administered prior to a standardized meal on two separate study days.
In this study, Pramlintide (Symlin) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Pramlintide (Symlin).
Report a problemFND-1769450507

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.